- GERN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $13.6 million.
- GERN has traded 402,333 shares today.
- GERN is down 3.9% today.
- GERN was up 25.6% yesterday.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in GERN with the Ticky from Trade-Ideas. See the FREE profile for GERN NOW at Trade-Ideas More details on GERN: Geron Corporation, a clinical stage biopharmaceutical company, develops a telomerase inhibitor, imetelstat, to treat hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California. Currently there are 2 analysts that rate Geron a buy, no analysts rate it a sell, and 2 rate it a hold. The average volume for Geron has been 2.0 million shares per day over the past 30 days. Geron has a market cap of $349.9 million and is part of the health care sector and drugs industry. The stock has a beta of 2.30 and a short float of 21.7% with 5.86 days to cover. Shares are down 40.9% year-to-date as of the close of trading on Monday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.